dd-cfDNA guidance cut felzartamab dosing by two-thirds in kidney rejection
A Lancet Regional Health extension of the Vienna Phase 2 trial reports biomarker-guided dosing preserved treatment success while sparing roughly two-thirds of drug exposure, though no numeric efficacy or safety data accompanied the claim.
Executive Summary
- A published extension of a completed Phase 2 trial reports that guiding felzartamab dosing with a donor-derived cell-free DNA blood test cut drug use by roughly two-thirds compared with fixed monthly dosing, while maintaining treatment success and a safety profile consistent with the drug's known effects.
- Felzartamab already carries FDA Breakthrough Therapy Designation for late antibody-mediated rejection in kidney transplants and has moved into two Phase 3 trials, so how this dosing strategy reads matters for how the drug's confirmatory program is run and priced.
- The publication's central dose-sparing figure is a qualitative characterization rather than a reported effect size, drawn from a small extension cohort, which limits how far the claim can travel before larger controlled data confirm it.
- Felzartamab operates in a CD38-targeted field for antibody-mediated rejection that includes two other early-stage entrants sharing the same target and modality, none yet approved in this indication, making this an early proof point in an unsettled treatment landscape rather than a competitive response to an established rival.
What was published
Insight Molecular Diagnostics Inc. said a new study in The Lancet Regional Health - Europe, an extension of the Phase 2 felzartamab trial run by the Medical University of Vienna, found that dosing guided by donor-derived cell-free DNA (dd-cfDNA) testing spared roughly two-thirds of drug use compared with unguided administration every four weeks. The extension followed patients from the original trial who continued to be monitored with iMDx's GraftAssure test and retreated whenever the biomarker signaled a recurrence of antibody-mediated rejection (AMR), a form of transplant rejection driven by donor-specific antibodies. iMDx Chief Science Officer Ekkehard Schuetz said the company is "cautious in our interpretations of small cohort studies" but called the dosing reduction "economically beneficial" and said the extended, biomarker-guided treatment was "safe and accompanied by long-lasting treatment success". iMDxiMDx GraftAssure Assay Guides Use of Potentially Kidney-Graft-Saving Drug in New Lancet Group ...Jul 23, 2026
Probability of SuccessBased on the AppliedXL Probability of Success model. For more information about the methodology, read the research here.
The trial behind it
NCT05021484 is a Phase 2, randomized, quadruple-masked trial that enrolled 22 kidney transplant recipients with active or chronic active antibody-mediated rejection, comparing felzartamab against placebo. Its registered primary endpoint was the incidence of treatment-emergent adverse events, with 17 secondary endpoints spanning molecular rejection scores, donor-specific antibody levels, and graft function. The trial completed in March 2024 after enrollment was finalized at 22 patients, unchanged from its adjusted target, and after its primary completion date was moved up by roughly six months during the study, from an anticipated October 2024 to March 2024. The felzartamab program has since advanced: it received FDA Breakthrough Therapy Designation for late AMR in October 2024, and Biogen has since moved the drug into two Phase 3 trials in the same indication. NCT05021484Felzartamab in Late Antibody-Mediated RejectionNCT05021484
Reading the result
The publication does not report a numeric effect size, p-value, or confidence interval for the two-thirds dose-sparing figure, and safety was characterized only as consistent with the drug's known profile rather than quantified. That leaves the central claim as a qualitative characterization from a 22-patient cohort rather than a reported statistic. The commercial framing compounds the caution: iMDx, which supplies the dd-cfDNA test used to guide dosing, presented the finding explicitly as a market-expansion opportunity for its own assay beyond its current use ruling out biopsies. The original NEJM publication on this same cohort had already established that dd-cfDNA testing could detect AMR recurrence roughly ten months earlier than standard monitoring, so this extension builds on a foundation with earlier, more concrete precedent. iMDxiMDx GraftAssure Assay Guides Use of Potentially Kidney-Graft-Saving Drug in New Lancet Group ...Jul 23, 2026
The competitive field
Felzartamab is one of three CD38-targeted antibodies in active development for antibody-mediated rejection: Biogen's own felzartamab Phase 3 programs (NCT06685757, NCT07444489), CASI Pharmaceuticals' CID-103 in Phase 1/2 (NCT07641426), and Takeda's mezagitamab in Phase 2 (NCT07613359). None has reached approval in this indication, and the broader CD38 competitive field elsewhere is anchored in multiple myeloma, where daratumumab and isatuximab are approved but only for that oncology setting, not for transplant rejection. No prior CD38-targeted trial in antibody-mediated rejection has failed or been terminated on record, which frames the mechanism as unproven rather than validated: the open question for this dosing strategy is whether a biomarker-guided regimen preserves the treatment effect that earned the Breakthrough designation once tested against a placebo control at scale in the ongoing Phase 3 trials. NCT05021484Felzartamab in Late Antibody-Mediated RejectionNCT05021484
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.